Bard Implantable Port Injury Lawyers

Mazie Slater Katz & Freeman is currently investigating Bard Implanted Port and Catheter claims.  Bard Implanted Ports and Catheters are devices designed to provide repeated access to the vascular system for the administration of medication, including chemotherapy.  Based on our investigation, the Implantable Ports and Catheters, also known as Power Ports or Port-a-Caths, are defective for a number of reasons, including the use of barium sulfate to coat the device, which is prone to degradation and fracturing, which was never adequately warned about by the manufacturer.

Bard Implantable Ports and Catheters have gone by the following names:

  • BardPort M.R.I. Implantable Port
  • BardPort M.R.I. Low-Profile Implantable Port
  • BardPort Titanium Dome Implantable Port
  • BardPort Titanium Implantable Port
  • M.R.I. Plastic Dual Lumen Port
  • M.R.I. Ultra SlimPort Implantable Port
  • Peritoneal Titanium Port
  • PowerFlow Implantable Apheresis IV Port
  • PowerPort ClearVUE isp Implantable Port
  • PowerPort ClearVUE Slim Implantable Port
  • PowerPort duo M.R.I. Implantable Port
  • PowerPort Implantable Port
  • PowerPort isp Implantable Port
  • PowerPort isp M.R.I. Implantable Port
  • PowerPort M.R.I. Implantable Port
  • PowerPort Slim Implantable Port
  • PowerPort VUE M.R.I. Implantable Port
  • PowerPort VUE Titanium Implantable Port
  • SlimPort Dual-Lumen Rosenblatt Implantable Port
  • Titanium Low-Profile Port
  • Titanium SlimPort Implantable Port
  • Vaccess CT Low-Profile Titanium Power-Injectable Port
  • Vaccess CT Power-Injectable Implantable Port
  • X-Port isp M.R.I. Implantable Port
  • X-Port Low-Profile Titanium Port

The Catheter is usually packaged with the Port.

The Food and Drug Administration (FDA) has received many adverse event reports from Bard Implantable Port and Catheter patients, and we are investigating claims for the following injuries:

  • Device Fracture – often resulting in shards of the catheters embedding in the heart or other internal structures
  • Thrombosis or Thrombotic Events (e.g., Thromboembolism, Myocardial infarction symptoms, Pulmonary embolism)
  • Infection
  •  Sepsis

A 2020 study of 9.,756 patients with implantable ports and catheters showed: “Any complication occurring within 5 years postoperatively was common (59.04%, n = 53,353). Arrhythmogenic (32.66%, n = 30,625) and thrombovascular (36.80%, n = 34,499) complications were more common than infection (17.86%, n = 16,745) and mechanical (10.31%, n = 9,670) complications.” Although the study was not limited to Bard Implantable Ports and Catheters, Bard is a market leader for implantable ports, so many of its devices were part of this study.

Three of the companies involved in the development, manufacture, and sale of Bard Implantable Ports—C.R. Bard, Inc., Bard Access Systems, Inc., and Becton Dickson—maintain their principal places of business in New Jersey. As a result, Mazie Slater, a New Jersey law firm, can file Bard Implantable Port and Catheter cases in New Jersey on behalf of patients from around the United States.

Mazie Slater has led litigations against pharmaceutical and medical device companies, including C.R. Bard, Inc., on behalf of thousands of patients. If you or someone you know has a potential Bard Implantable Port claim, contact one of our qualified Bard Implantable Port attorneys today for a free consultation.

Bard Implantable Port Injury Lawyers

Mazie Slater Katz & Freeman is currently investigating Bard Implanted Port and Catheter claims.  Bard Implanted Ports and Catheters are devices designed to provide repeated access to the vascular system for the administration of medication, including chemotherapy.  Based on our investigation, the Implantable Ports and Catheters, also known as Power Ports or Port-a-Caths, are defective for a number of reasons, including the use of barium sulfate to coat the device, which is prone to degradation and fracturing, which was never adequately warned about by the manufacturer.

Bard Implantable Ports and Catheters have gone by the following names:

  • BardPort M.R.I. Implantable Port
  • BardPort M.R.I. Low-Profile Implantable Port
  • BardPort Titanium Dome Implantable Port
  • BardPort Titanium Implantable Port
  • M.R.I. Plastic Dual Lumen Port
  • M.R.I. Ultra SlimPort Implantable Port
  • Peritoneal Titanium Port
  • PowerFlow Implantable Apheresis IV Port
  • PowerPort ClearVUE isp Implantable Port
  • PowerPort ClearVUE Slim Implantable Port
  • PowerPort duo M.R.I. Implantable Port
  • PowerPort Implantable Port
  • PowerPort isp Implantable Port
  • PowerPort isp M.R.I. Implantable Port
  • PowerPort M.R.I. Implantable Port
  • PowerPort Slim Implantable Port
  • PowerPort VUE M.R.I. Implantable Port
  • PowerPort VUE Titanium Implantable Port
  • SlimPort Dual-Lumen Rosenblatt Implantable Port
  • Titanium Low-Profile Port
  • Titanium SlimPort Implantable Port
  • Vaccess CT Low-Profile Titanium Power-Injectable Port
  • Vaccess CT Power-Injectable Implantable Port
  • X-Port isp M.R.I. Implantable Port
  • X-Port Low-Profile Titanium Port

The Catheter is usually packaged with the Port.

The Food and Drug Administration (FDA) has received many adverse event reports from Bard Implantable Port and Catheter patients, and we are investigating claims for the following injuries:

  • Device Fracture – often resulting in shards of the catheters embedding in the heart or other internal structures
  • Thrombosis or Thrombotic Events (e.g., Thromboembolism, Myocardial infarction symptoms, Pulmonary embolism)
  • Infection
  •  Sepsis

A 2020 study of 9.,756 patients with implantable ports and catheters showed: “Any complication occurring within 5 years postoperatively was common (59.04%, n = 53,353). Arrhythmogenic (32.66%, n = 30,625) and thrombovascular (36.80%, n = 34,499) complications were more common than infection (17.86%, n = 16,745) and mechanical (10.31%, n = 9,670) complications.” Although the study was not limited to Bard Implantable Ports and Catheters, Bard is a market leader for implantable ports, so many of its devices were part of this study.

Three of the companies involved in the development, manufacture, and sale of Bard Implantable Ports—C.R. Bard, Inc., Bard Access Systems, Inc., and Becton Dickson—maintain their principal places of business in New Jersey. As a result, Mazie Slater, a New Jersey law firm, can file Bard Implantable Port and Catheter cases in New Jersey on behalf of patients from around the United States.

Mazie Slater has led litigations against pharmaceutical and medical device companies, including C.R. Bard, Inc., on behalf of thousands of patients. If you or someone you know has a potential Bard Implantable Port claim, contact one of our qualified Bard Implantable Port attorneys today for a free consultation.

Read More
Watch Our Attorneys

On Television and in Court

View All Media Media Networks